GE Healthcare Pharmaceutical Diagnostics offers a variety of educational programs related to ultrasound and ultrasound enhancing agents
including Optison™ (Perflutren Protein-Type A Microspheres Injectable Suspension, USP).
FREE CE credits are available for eligible recipients from the Society of Diagnostic Medical Sonography (SDMS).
New courses are added throughout the year, so be sure to check back frequently!

See Optison Important Safety Information, including Boxed Warning, below.

Optimizing Optison Images
Optimizing Optison Images: Case 1-16

Conference Multi Offering

Adult Echo .5 CME credits for each case

Target Audience: Sonographers

Duration:
30 minutes total
20 minutes lecture
10 minutes hands-on

Objectives
  • Identify contraindications and precautions associated with the delivery of contrast
  • Describe the process of resuspension, venting, and injection.
  • Identify appropriate dosing and administration of contrast
  • Define the function of basic UEA physics as it relates to system knobology
  • Demonstrate optimal system setting including power, gain, compression, DR, and DDP
  • Identify optimal transducer position to visualize the presence of contrast to aid in identifying pathology
  • Apply findings to determine if the case was diagnostic
  • Describe the technique by which to produce a diagnostic study
GE Contracted Speakers

If you are interested in participating in the following course, please fill out the information below. You will be contacted shortly.






   Optimizing Optison Images



Want to find out more about GE Healthcare's Optison?
Click here to visit the product promotional page.
INDICATIONS AND USAGE
OPTISON (Perflutren Protein-Type A Microspheres Injectable Suspension, USP) is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricle and to improve the delineation of the left ventricular endocardial borders.

IMPORTANT SAFETY INFORMATION
WARNING: SERIOUS CARDIOPULMONARY REACTIONS
Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following perflutren-containing microsphere administration.
Most serious reactions occur within 30 minutes of administration
• Assess all patients for the presence of any condition that precludes OPTISON administration
• Always have resuscitation equipment and trained personnel readily available

CONTRAINDICATION: Do not administer OPTISON to patients with known or suspected hypersensitivity to perflutren or albumin.

WARNINGS AND PRECAUTIONS: Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or shortly following administration. The risk for these reactions may be increased among patients with unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, or serious ventricular arrhythmias).

• Serious anaphylactic reactions have been observed during or shortly following perflutren-containing microsphere administration, including shock, hypersensitivity, bronchospasm, throat tightness, angioedema, edema (pharyngeal,palatal, mouth, peripheral, localized), swelling (face, eye, lip, tongue, upper airway), facial hypoesthesia, rash, urticaria, pruritus, flushing, and erythema have occurred in patients with no prior exposure to perflutren-containing microsphere products.

• When administering OPTISON to patients with a cardiac shunt, microspheres can bypass filtering of the lungs and enter the arterial circulation. Assess patients with shunts for embolic phenomena following OPTISON administration.

• High ultrasound mechanical index values may cause microsphere rupture and lead to ventricular arrhythmias. Additionally, end-systolic triggering with high mechanical indices has been reported to cause ventricular arrhythmias. OPTISON is not recommended for use at mechanical indices greater than 0.8.

• This product contains albumin, a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral disease.

ADVERSE EVENTS: The most frequently reported adverse reactions in clinical trials were headache, nausea and/or vomiting, warm sensation or flushing and dizziness. Cardiac arrests and other serious but nonfatal adverse reactions were uncommonly reported in post-approval use. Reports also identified neurologic reactions (loss of consciousness or convulsions) as well as anaphylactoid reactions.

Please see the full Prescribing Information, including Boxed Warning for additional important safety information.

To report SUSPECTED ADVERSE REACTIONS, contact GE Healthcare at 800 654 0118 (option 2, then option 1), or the FDA at 800 FDA 1088 or www.fda.gov/medwatch
IMPORTANT SAFETY INFORMATION
WARNING: SERIOUS CARDIOPULMONARY REACTIONS
Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following perflutren-containing microsphere administration. Most serious reactions occur within 30 minutes of administration
• Assess all patients for the presence of any condition that precludes OPTISON administration
• Always have resuscitation equipment and trained personnel readily available

CONTRAINDICATION: Do not administer OPTISON to patients with known or suspected hypersensitivity to perflutren or albumin.
PRODUCT INDICATIONS
OPTISON™ (Perflutren Protein-Type A Microspheres Injectable Suspension, USP
OPTISON is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricle and to improve the delineation of the left ventricular endocardial borders.
Do not administer OPTISON to patients with known or suspected: (1) Right-to-left, bidirectional, or transient right-to-left cardiac shunts or (2) Hypersensitivity to perflutren, blood, blood products, or albumin. Do not administer OPTISON by intra-arterial injection.

Access the full Prescribing Information here.

August 2021 JB05521US

➤ see moreINDICATIONS AND USAGE
OPTISON (Perflutren Protein-Type A Microspheres Injectable Suspension, USP) is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricle and to improve the delineation of the left ventricular endocardial borders.

IMPORTANT SAFETY INFORMATION
WARNING: SERIOUS CARDIOPULMONARY REACTIONS
Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following perflutren-containing microsphere administration. Most serious reactions occur within 30 minutes of administration
• Assess all patients for the presence of any condition that precludes OPTISON administration
• Always have resuscitation equipment and trained personnel readily available


• CONTRAINDICATION: Do not administer OPTISON to patients with known or suspected hypersensitivity to perflutren or albumin.

• WARNINGS AND PRECAUTIONS: Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or shortly following administration. The risk for these reactions may be increased among patients with unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, or serious ventricular arrhythmias).

• Serious anaphylactic reactions have been observed during or shortly following perflutren-containing microsphere administration, including shock, hypersensitivity, bronchospasm, throat tightness, angioedema, edema (pharyngeal,palatal, mouth, peripheral, localized), swelling (face, eye, lip, tongue, upper airway), facial hypoesthesia, rash, urticaria, pruritus, flushing, and erythema have occurred in patients with no prior exposure to perflutren-containing microsphere products.

• When administering OPTISON to patients with a cardiac shunt, microspheres can bypass filtering of the lungs and enter the arterial circulation. Assess patients with shunts for embolic phenomena following OPTISON administration.

• High ultrasound mechanical index values may cause microsphere rupture and lead to ventricular arrhythmias. Additionally, end-systolic triggering with high mechanical indices has been reported to cause ventricular arrhythmias. OPTISON is not recommended for use at mechanical indices greater than 0.8.

• This product contains albumin, a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral disease.

• ADVERSE EVENTS: The most frequently reported adverse reactions in clinical trials were headache, nausea and/or vomiting, warm sensation or flushing and dizziness. Cardiac arrests and other serious but nonfatal adverse reactions were uncommonly reported in post-approval use. Reports also identified neurologic reactions (loss of consciousness or convulsions) as well as anaphylactoid reactions.

To report SUSPECTED ADVERSE REACTIONS, contact GE Healthcare at 800 654 0118 (option 2, then option 1), or the FDA at 800 FDA 1088 or www.fda.gov/medwatch